PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
NCT06156878
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
41
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
COMBINATION_PRODUCT:
Anti-EGFR and PD-1 inhibitor arm
Sponsor
Fudan University